Evidence map›Paper›PMID 42606562›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

Prognostic relevance of [18F]FDG PET/CT in triple-negative breast cancer: Results from the triple negative (TRINE)-PET trial.

Luca Urso, Stefano Panareo, Domenico Albano, Antonella Iudicello, Luca Filippi, Francesca Borgia, Mirco Bartolomei, Priscilla Guglielmo, Francesco Bertagna, Silvia Taralli and 25 more

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors.

Luca UrsoDepartment of Translational Medicine, University of Ferrara, Via Aldo Moro N.8, Ferrara, Italy. luca.urso@unife.it.ORCID http://orcid.org/0000-0002-3007-3898
Stefano PanareoNuclear Medicine Unit, Oncology and Hematology Department, University Hospital of Modena, Modena, Italy.
Domenico AlbanoNuclear Medicine, University of Brescia, Brescia, Italy.
Antonella IudicelloNuclear Medicine Unit, Onco-Hematology Department, University Hospital of Ferrara, Ferrara, Italy.
Luca FilippiDepartment of Biomedicine and Prevention, University Tor Vergata, Rome, Italy.
Francesca BorgiaDepartment of Translational Medicine, University of Ferrara, Via Aldo Moro N.8, Ferrara, Italy.
Mirco BartolomeiNuclear Medicine Unit, Onco-Hematology Department, University Hospital of Ferrara, Ferrara, Italy.
Priscilla GuglielmoDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy.
Francesco BertagnaNuclear Medicine, University of Brescia, Brescia, Italy.
Silvia TaralliNuclear Medicine Unit, Diagnostic Imaging and Radiation Oncology Department, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Maria Lucia CalcagniNuclear Medicine Unit, Diagnostic Imaging and Radiation Oncology Department, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Angelica MazzolettiNuclear Medicine "Alessandra Bono", Fondazione Poliambulanza Istituto Ospedaliero, Brescia, Italy.
Mattia BonacinaNuclear Medicine "Alessandra Bono", Fondazione Poliambulanza Istituto Ospedaliero, Brescia, Italy.
Lorenzo FantiniNuclear Medicine Department, IRCCS Istituto Romagnolo Per Lo Studio Dei Tumori "Dino Amadori" (IRST), Meldola, Italy.
Andrea PaccagnellaNuclear Medicine Service, 'M. Bufalini' Hospital, 'Azienda Unità Sanitaria Locale' Romagna, Cesena, Italy.
Carlotta Benedetta ColomboNuclear Medicine Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Massimo CastellaniNuclear Medicine Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Alessio AnnovazziNuclear Medicine Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Rosa SciutoNuclear Medicine Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Matteo BaucknehtIRCCS Azienda Ospedaliera Metropolitana, Genova, Italy.
Federico GarrouNuclear Medicine, AOU Maggiore Della Carità, Novara, Italy.
Demetrio AricòNuclear Medicine Unit, Humanitas Istituto Clinico Catanese, Catania, Italy.
Guido RoveraNuclear Medicine Division, Department of Medical Sciences, AOU Città Della Salute E Della Scienza Di Torino, University of Turin, Turin, Italy.
Cristina FerrariDepartment of Nuclear Medicine, University Aldo Moro, Bari, Italy.
Alberto MiceliDepartment of Nuclear Medicine, Azienda Ospedaliero-Universitaria SS. Antonio E Biagio E Cesare Arrigo, Alessandria, Italy.
Pasquale RecciaUnit of Nuclear Medicine and Molecular Imaging, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.
Gianluca CassarinoNuclear Medicine Unit, Giovanni Paolo II Hospital, Ragusa, Italy.
Elisa RizzaNuclear Medicine Unit, Vito Fazzi Hospital, Lecce, Italy.
Andrea MarongiuUnit of Nuclear Medicine. Department of Medicine, Surgery and Pharmacy, University of Sassari, Sassari, Italy.
Annachiara ArnoneDepartment of Nuclear Medicine, Azienda Unità Sanitaria Locale-IRCCS Di Reggio Emilia, Reggio Emilia, Italy.
Anna Margherita MaffioneDepartment of Nuclear Medicine, S.M. Della Misericordia Hospital, Rovigo, Italy.
Salvatore IalunaNuclear Medicine Unit, Ospedali Riuniti Villa Sofia-Cervello, 90146, Palermo, Italy.
Nicola FregaNuclear Medicine Unit, Department of Health Service, AORN Ospedali Dei Colli, Naples, Italy.
Laura EvangelistaDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy.
All the TRINE-PET Investigators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTriple negative breast cancer (TNBC) is an aggressive subtype, still with limited therapeutic options. [

methodsThis retrospective multicenter study included 389 TNBC patients who underwent 707 [

resultsDuring a median follow up of 34 months (1-124), disease progression and death occurred in 39.3% and 28.4% of cases, respectively. Across all clinical settings, nodal and distant metastatic involvement at [

conclusionIn the largest real world multicenter study dedicated to TNBC, [

Indexed as

FDGPETPrognosisSurvivalTriple negative breast cancer

Identifiers

PMID42606562

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.